Infinity Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Infinity Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	36.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Infinity Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

DB:I3F - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2023	3	-41	-39	-39	N/A
3/31/2023	3	-43	-41	-41	N/A
12/31/2022	3	-44	-42	-42	N/A
9/30/2022	3	-47	-43	-43	N/A
6/30/2022	2	-47	-42	-42	N/A
3/31/2022	2	-46	-41	-41	N/A
12/31/2021	2	-45	-41	-41	N/A
9/30/2021	2	-44	-39	-39	N/A
6/30/2021	2	-43	-39	-39	N/A
3/31/2021	2	-41	-37	-37	N/A
12/31/2020	2	-40	-36	-36	N/A
9/30/2020	2	-41	-37	-36	N/A
6/30/2020	1	-43	-40	-38	N/A
3/31/2020	1	-44	-40	-38	N/A
12/31/2019	3	-47	-44	-42	N/A
9/30/2019	3	-44	-18	-16	N/A
6/30/2019	25	-19	-14	-13	N/A
3/31/2019	24	-16	-11	-11	N/A
12/31/2018	22	-11	-5	-5	N/A
9/30/2018	22	-10	-20	-20	N/A
6/30/2018	6	-31	-24	-24	N/A
3/31/2018	6	-41	-29	-29	N/A
12/31/2017	6	-42	-37	-37	N/A
9/30/2017	6	-57	-59	-59	N/A
6/30/2017	N/A	-70	-83	-83	N/A
3/31/2017	9	0	N/A	-120	N/A
12/31/2016	19	-30	N/A	-154	N/A
9/30/2016	28	-46	N/A	-51	N/A
6/30/2016	119	15	N/A	-50	N/A
3/31/2016	114	-76	N/A	-36	N/A
12/31/2015	109	-128	N/A	-84	N/A
9/30/2015	104	-129	N/A	-213	N/A
6/30/2015	174	-71	N/A	60	N/A
3/31/2015	169	-68	N/A	62	N/A
12/31/2014	165	-17	N/A	118	N/A
9/30/2014	161	-10	N/A	128	N/A
6/30/2014	N/A	-145	N/A	-136	N/A
3/31/2014	N/A	-142	N/A	-132	N/A
12/31/2013	N/A	-127	N/A	-114	N/A
9/30/2013	N/A	-141	N/A	-114	N/A
6/30/2013	0	-88	N/A	-118	N/A
3/31/2013	22	-71	N/A	-94	N/A
12/31/2012	47	-54	N/A	-80	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de I3F es superior a la tasa de ahorro (0.5%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de I3F crezcan más rápidamente que el mercado German

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de I3F crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de I3F crezcan más rápidamente que el mercado de German.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de I3F crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de I3F se prevé que sea elevada dentro de 3 años.

Infinity Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Forecast to breakeven in 2024

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.50 loss per share (vs US$0.53 loss in FY 2021)

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2021)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021)

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 1Q 2021)

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings released: US$0.53 loss per share (vs US$0.68 loss in FY 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: €4.00

New 90-day high: €2.00

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

New 90-day high: €1.95

New 90-day high: €1.45

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - €1.03

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento